Princeton, New Jersey, October 16, 2015 – Sandoz today announced the US introduction of fluvastatin sodium extended-release tablets, USP, an authorized generic version (AGx) of LESCOL® XL, which is marketed by Novartis Pharmaceuticals Corporation. This is another great example of cross-divisional collaboration in the context of the ongoing Novartis Group Rx-Gx program.

Fluvastatin sodium extended-release tablets, USP are indicated as an adjunctive therapy with changes to diet to lower cholesterol, slow the progression of heart disease and reduce the risk of needing …